Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Intervention Indication Therapeutic Area Year Actions
Depemokimab as adjunctive therapy for severe asthma with an eosinophilic phenotype in patients aged 12 years and older Depemokimab Asthma Respiratory System 2024 View  |  Download
Depatuxizumab mafodotin for newly diagnosed EGFR‐amplified glioblastoma – first line Depatuxizumab mafodotin (ABT-414) , Temozolomide (Temodar; Temodal; SCH 52365) Glioma Neurological Cancer 2018 View  |  Download
Denosumab for the prevention of skeletal related events in patients with multiple myeloma – first line Denosumab (AMG 162; Prolia; Xgeva) Prevention of skeletal related events in multiple myeloma Haematological Cancer and Lymphomas , Musculoskeletal System 2017 View  |  Download
Denosumab biosimilar for treating postmenopausal osteoporosis Denosumab biosimilar Postmenopausal osteoporosis Musculoskeletal System 2022 View  |  Download
Delgocitinib for treating moderate to severe chronic hand eczema after 1 previous therapy Delgocitinib Chronic hand eczema Dermatology 2023 View  |  Download
Degarelix acetate prior to or with radiotherapy for prostate cancer Degarelix acetate , Radiotherapy Prostate cancer Male Reproductive Cancer 2023 View  |  Download
Deferiprone for transfusional iron overload in sickle cell disease and other anaemias – First Line Deferiprone (Ferriprox) Iron overload Endocrine Nutritional and Metabolic Disorders , Haematology 2020 View  |  Download
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Datopotamab deruxtecan (DS-1062) Breast cancer Breast Cancer 2024 View  |  Download
Datopotamab deruxtecan for previously treated unresectable or metastatic HR+ HER2- breast cancer Datopotamab deruxtecan (DS-1062) Breast cancer Breast Cancer 2023 View  |  Download
Datopotamab deruxtecan for previously treated advanced non-small-cell lung cancer Datopotamab deruxtecan (DS-1062) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
1 2 85 86 87 88 89 113 114
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications